Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer

Lung cancers globally account for 12% of new cancer cases, 85% of these being Non Small Cell Lung Cancer (NSCLC). Therapies like erlotinib target the key player EGFR, which is mutated in about 10% of lung adenocarcinoma. However, drug insensitivity and resistance caused by second mutations in the EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Praveen, Paurush, Hülsmann, Helen, Sültmann, Holger, Kuner, Ruprecht, Fröhlich, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899720/
https://www.ncbi.nlm.nih.gov/pubmed/27279498
http://dx.doi.org/10.1038/srep27514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899720/
https://www.ncbi.nlm.nih.gov/pubmed/27279498
http://dx.doi.org/10.1038/srep27514

Ejemplares similares